8-KEarnings & ResultsExhibits & Filings

Cigna Group 8-K Report, Financial Results (Feb 2, 2024)

Filed February 2, 2024For Securities:CI

Summary

The Cigna Group (CI) filed an 8-K on February 2, 2024, to announce its financial results for the fourth quarter and full year ended December 31, 2023. The primary purpose of this filing is to furnish the associated press release, which contains the detailed operational and financial performance of the company. Investors should refer to the furnished press release (Exhibit 99.1) for specific metrics and commentary on the company's performance and financial condition. This report does not introduce new definitive financial statements or material agreements beyond what is contained in the press release. The filing serves as a formal notification to the SEC and the market regarding the release of these results, which are crucial for evaluating the company's recent performance, strategic execution, and future outlook. Shareholders and potential investors are encouraged to review the press release for a comprehensive understanding of Cigna's financial standing and operational achievements during the period.

Key Highlights

  • 1Cigna Group announced its financial results for the three months and year ended December 31, 2023, via a press release furnished with this 8-K filing.
  • 2The press release is incorporated by reference, serving as the primary source of detailed financial and operational data.
  • 3The filing formally notifies the market and the SEC of the release of Q4 and full-year 2023 results.
  • 4Key financial metrics and performance indicators are expected to be detailed within the press release (Exhibit 99.1).
  • 5This 8-K serves as a procedural filing, directing investors to the press release for substantive information.
  • 6The Chief Financial Officer, Brian C. Evanko, signed the report, indicating the official release of the financial information.

Frequently Asked Questions

The detailed financial results are provided in the press release dated February 2, 2024, which is furnished as Exhibit 99.1 to this 8-K filing and incorporated by reference. Investors should refer to this press release for specific financial figures and operational commentary.

No, this 8-K filing primarily serves to announce and furnish the press release containing the company's Q4 and full-year 2023 results. It does not introduce new definitive financial statements or material agreements beyond what is detailed in the press release itself.

The event date (February 1, 2024) likely reflects when the results were finalized or approved internally, while the filing date (February 2, 2024) is when The Cigna Group officially submitted the 8-K to the SEC, concurrently releasing the press release. This timing ensures prompt disclosure of material financial information to investors.

The 8-K filing was signed by Brian C. Evanko, Executive Vice President and Chief Financial Officer, and President and Chief Executive Officer of Cigna Healthcare. This signature signifies the official endorsement and release of the company's financial results by its senior financial leadership.